复发性上皮性卵巢癌患者腹腔输注干细胞来源自然杀伤细胞的1期INTRO-01试验结果
INTRO-01为首次人体1期试验,评估腹腔输注脐带血造血干祖细胞体外衍生的NK细胞产品RNK001在二次复发且CA125升高的上皮性卵巢癌患者中的可行性、安全性和毒性,7例中5例输注后14天CA125下降20-53%,未出现移植物抗宿主病或细胞因子释放综合征。
要点
- 腹腔输注RNK001未出现移植物抗宿主病或细胞因子释放综合征。
- 7例中5例输注后14天CA125血清水平下降20-53%。
- 1例达临床和生化缓解,影像学疾病稳定,无进展生存期9个月。
核心结论
- 腹腔RNK001免疫治疗可安全用于复发性上皮性卵巢癌患者而不引起严重毒性,临床和生化缓解值得进一步开发。
研究设计与样本
- 首次人体1期INTRO-01试验(NCT03539406),评估腹腔输注RNK001在二次复发且CA125升高的上皮性卵巢癌患者中的可行性、安全性和毒性。
- RNK001为脐带血造血干祖细胞体外衍生的NK细胞产品,含1.2至3.0×10^9个高活化CD56+CD3- NK细胞。
- 6例患者腹腔输注RNK001并辅以腹腔IL-2,1例在输注前接受环磷酰胺/氟达拉滨淋巴细胞清除化疗。
主要发现
- RNK001耐受良好,未出现移植物抗宿主病或细胞因子释放综合征。
- 1例出现3级一过性肝酶升高,另1例出现由疾病进展导致的3级肠梗阻。
- 7例中5例在输注后14天CA125血清水平下降20-53%。
- 1例达临床和生化缓解,影像学疾病稳定,无进展生存期9个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Epithelial ovarian cancer (EOC) patients exhibit a poor 5-year overall survival rate of approximately 40 %, underscoring the urgent need for innovative therapies. Allogeneic natural killer (NK) cell therapy presents a promising and safe therapeutic option, given its ability to discriminate between normal and malignant cells with potent cytotoxic effects against malignant cells. METHODS: We present the first-in-human study exploiting the safety of the NK cell product designated RNK001, derived ex vivo from umbilical cord blood-derived hematopoietic stem and progenitor cells. This phase 1 INTRO-01 trial (NCT03539406) was initiated to assess the feasibility, safety, and toxicity of intraperitoneal (IP) infusion of RNK001 in EOC patients exhibiting elevated CA125 levels at the second recurrence. RNK001 infusion was supported by IP IL-2 in six patients, and was preceded in one patient by lymphodepleting chemotherapy with cyclophosphamide/fludarabine. RESULTS: RNK001 consisted of 1.2 to 3.0 × 109 highly activated CD56+CD3- NK cells and was well tolerated, with neither evidence of graft-versus-host disease nor cytokine release syndrome. One patient experienced a grade 3 transient elevation in liver enzymes, another patient exhibited grade 3 ileus caused by disease progression. Notably, five out seven patients demonstrated a reduction in CA125 serum levels of 20-53 % at 14 days post-infusion. Furthermore, one patient achieved a clinical and biochemical response with radiological stable disease and a progression-free survival of 9 months. CONCLUSION: These findings suggest that intraperitoneal RNK001-based immunotherapy can be safely administered to recurrent EOC patients without inducing severe toxicity, while clinical and biochemical responses warrant further development.
引用
- Hoogstad-van Evert JS, de Jonge PKJD, Zusterzeel PLM, et al. Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial. Gynecol Oncol. 2025. PMID: 41289795. doi:10.1016/j.ygyno.2025.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。